Every material Form 8-K Collegium Pharmaceutical filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Collegium reported third-quarter 2024 product revenue of $159.3 million, up 17% year over year, while GAAP net income fell to $9.3 million from $20.6 million a year earlier. The company reaffirmed its full-year 2024 product revenue guidance of $620.0 million to $635.0 million and said Vikram Karnani will become President and Chief Executive Officer effective November 12, 2024, succeeding Michael Heffernan, who remains Chairman.
Q3 2024 product revenue was $159.3 million versus $136.7 million a year earlier; GAAP diluted EPS was $0.27 versus $0.53
Q3 2024 adjusted EBITDA was $105.1 million, up 18% from $89.4 million; GAAP operating expenses rose to $62.0 million from $35.3 million
Full-year 2024 guidance reaffirmed: product revenue $620.0 million to $635.0 million, adjusted EBITDA $395.0 million to $405.0 million
Karnani's agreement includes a $875,000 base salary, a 75% target bonus, a $500,000 signing bonus and $10 million in equity awards
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Collegium Pharmaceutical filing is on SEC EDGAR ↗. 8-K briefs of other companies →